Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...
FiercePharma5h
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
The Pharma Letter2h
Erleada shows clinically-meaningful improvement in prostate cancer OS
Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...
JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer
(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...
J&J prostate cancer therapy outperforms in real-world study
Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...
The Daily Telegraph23h
World News
Videos show Russian flags raised over the shattered town of Vuhledar, which Kremlin troops failed to capture on two previous attempts ...